A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

• Drug: PF-05161704 or Placebo
  
  PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
• Drug: PF-05161704 or Placebo
  
  PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
• Drug: PF-05161704 or Placebo
  
  PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast

• Experimental: 5 mg PF-05161704 or Placebo
  
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: 15 mg PF-05161704 or Placebo
  
  Planned dose: may be modified based on emerging PK and safety data.
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: 50 mg PF-05161704 or Placebo
  
  Planned dose: may be modified based on emerging PK and safety data.
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: 150 mg PF-05161704 or Placebo
  
  Planned dose: may be modified based on emerging PK and safety data.
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: xx mg PF-05161704 or Placebo
  
  Planned dose and dosing regimen will be determined based on emerging PK and safety data.
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: xxx mg PF-05161704 or Placebo
  
  Dose will be determined based on data from previous 5 arms.
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: yy mg PF-05161704 or Placebo
  
  Dose will be determined based on data from previous 6 arms
  Intervention: Drug: PF-05161704 or Placebo
• Experimental: yyy mg PF-05161704 or Placebo
  
  Dose will be determined based on data from previous 7 arms.
  Intervention: Drug: PF-05161704 or Placebo

Inclusion Criteria:

• Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years, inclusive
• Body Mass Index (BMI) of 24.5 to 35.5 kg/m2 and a total body weight >50 kg (110 lbs.)

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Any condition possibly affecting drug absorption (e.g., gastrectomy).
• History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
• History or evidence of habitual use of tobacco or nicotine containing products within 3 months of screening or positive cotinine test at screening or Day -1.